EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity

Chunmei Fu, Tianle Ma, Björn E Clausen iD, Ira Mellman, Aimin Jiang iD

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2518080123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Chunmei Fu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health, Detroit, MI 48202. Hauptthemen laut MEDLINE: Dendritic Cells, Cancer Vaccines, Hepatitis A Virus Cellular Receptor 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henry Ford Health System (Henry Ford Health), Melanoma Research Alliance (MRA), Foundation for the National Institutes of Health (FNIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional type 1 dendritic cells (cDC1s) are specialized for cross-presenting tumor antigens and determining the efficacy of immunotherapies, including immune checkpoint blockade and adoptive cell therapy. However, their rarity and tumor-induced dysfunction severely limit CD8 T cell priming and represent a central bottleneck to therapeutic efficacy. While strategies such as anti–DEC-205-mediated antigen delivery and Flt3L-driven DC expansion can enhance host DC function, their reliance on functional cDC1s remains a significant constraint. We developed Tim-3-targeted vaccines by conjugating tumor antigens or neoantigens to anti–Tim-3 antibodies. These vaccines delivered antigens to both cDC1s and cDC2s, and elicited robust, durable CD8 T cell responses. Remarkably, Tim-3-targeted vaccines endowed cDC2s with efficient cross-presentation capacity that matched that of cDC1s. In tumor-bearing mice or in CD11c-β-catenin active mice, which model β-catenin-driven DC dysfunction, Tim-3-targeted vaccination restored cross-priming and counteracted tumor- and DC-mediated immunosuppression. In Batf3 −/− mice lacking cDC1s, anti-Tim-3-based vaccines still elicited significant CD8 T cell cross-priming and tumor control—albeit both were reduced compared to wild-type mice— demonstrating that cDC1s contribute to but are not essential for Tim-3-targeted vaccine–induced CD8 T cell priming and anti-tumor efficacy. Strikingly, a single dose of anti-Tim-3–neoantigen vaccination eradicated large established MC38 tumors in a CD8 T cell–dependent manner. Together, these data identify Tim-3-targeted vaccines as a next-generation cancer vaccine platform that broadens DC engagement, reduces reliance on cDC1s, and overcomes tumor- and DC-mediated immunosuppression, addressing key limitations of current DC-based cancer vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsCancer VaccinesHepatitis A Virus Cellular Receptor 2AnimalsMiceCD8-Positive T-LymphocytesAntigens, NeoplasmCross-PrimingMice, Inbred C57BLImmune ToleranceRepressor ProteinsMice, KnockoutBasic-Leucine Zipper Transcription Factors

Stichwörter der Autor:innen

Tim-3-targeted vaccinesanti-tumor CD8 T cell immunitydendritic cellstype 1 conventional DCstype 2 conventional DCs

Substanzen

Cancer VaccinesHepatitis A Virus Cellular Receptor 2Antigens, NeoplasmSNFT protein, mouseHavcr2 protein, mouseRepressor ProteinsBasic-Leucine Zipper Transcription Factors

Autor:innen und Institutionen

  • Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health, Detroit, MI 48202.
  • Immunology Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, MI 48202.
  • Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI 48824.
  • Department of Computer Science and Engineering, School of Engineering and Computer Science, Oakland University, Rochester, MI 48309.
  • Institute for Molecular Medicine and Research Center for Immunotherapy, University Medical Center of the Johannes Gutenberg-University, Mainz 55131, Germany.
  • Department of Biochemistry and Biophysics, School of Medicine, University of California, San Francisco, CA 94143.

ORCID-Profile: Björn E Clausen, Aimin Jiang

Förderung

  • Henry Ford Health System (Henry Ford Health)
  • Melanoma Research Alliance (MRA)
  • Foundation for the National Institutes of Health (FNIH)

Zitieren

APA

Fu, C., Ma, T., Clausen, B. E., Mellman, I., & Jiang, A. (2026). Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2518080123

Vancouver

Fu C, Ma T, Clausen BE, Mellman I, Jiang A. Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2518080123

BibTeX
@article{Fu2026,
  author = {Fu, Chunmei and Ma, Tianle and Clausen, Björn E and Mellman, Ira and Jiang, Aimin},
  title = {Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2518080123}
}
Kostenlos starten →